10:40 AM EDT, 07/09/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) said Tuesday that it received a new patent from the US Patent and Trademark Office covering its platform molecular residual disease, or MRD, technology.

The company said the new patent specifically relates to the technology's method in detecting circulating tumor DNA in patient fluid samples, such as blood and plasma. Myriad Genetics ( MYGN ) said this is the second patent awarded for its MRD assay development.

Price: 24.93, Change: -0.34, Percent Change: -1.33